TANG CAPITAL PARTNERS LP - 31 Dec 2024 SCHEDULE 13G/A Report for Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share (OTLK)

Filing Manager
TANG CAPITAL PARTNERS LP
Reporting Manager
TANG CAPITAL MANAGEMENT, LLC
Security
Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share
Symbol
OTLK
Shares outstanding
26,289,094 shares
Disclosed Ownership
1,682,502 shares
Ownership
6.4%
Form type
SCHEDULE 13G/A
Filing time
14 Feb 2025, 16:00:04 UTC
Date of event
31 Dec 2024
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"TANG CAPITAL PARTNERS LP disclosed 6.4% ownership in Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share (OTLK) on 31 Dec 2024."

Quick Takeaways

  • TANG CAPITAL PARTNERS LP filed SCHEDULE 13G/A for Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share (OTLK).
  • Disclosed ownership: 6.4%.
  • Date of event: 31 Dec 2024.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Feb 2025, 16:00.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
TANG CAPITAL MANAGEMENT, LLC 6.4% 1,682,502 0 1,682,502 /s/ Kevin Tang Manager
KEVIN TANG 6.4% 1,682,502 0 1,682,502 /s/ Kevin Tang Self
TANG CAPITAL PARTNERS, LP 5.9% 1,555,862 0 1,555,862 /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner
TANG CAPITAL PARTNERS III, INC 0.5% 126,640 0 126,640 /s/ Kevin Tang Chief Executive Officer
TANG CAPITAL PARTNERS IV, INC 0% 0 0 0 /s/ Kevin Tang Chief Executive Officer

Sponsored